Evaluation of levels of IL-2 and TNF- α in the serum of psoriasis patients and their role in inflammatory activity
DOI:
https://doi.org/10.36320/ajb/v18.i2.22802Keywords:
Psoriasis, interleukin-2, tumor necrosis factor alpha, cytokines, ELISA techniqueAbstract
Psoriasis is a chronic, inflammatory, immune-mediated skin disorder, which is characterized by hyperplasia of keratinocytes and long-term cellular immunity. Pro-inflammatory cytokines, especially interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α), are the basis of the pathogenesis and progression of the disease.Aim: The study was intended to determine the serum levels of IL-2 and TNF-α in psoriasis patients and to determine the correlation of these variables with clinical severity and other variables of clinical concern.Materials and Methods: Fifty clinically diagnosed patients with psoriasis and fifty age- and sex-matched controls (apparently healthy subjects) were involved in the study. The serum levels of IL-2 and TNF-α were determined using enzyme-linked immunosorbent assay (ELISA). The Psoriasis Area and Severity Index (PASI) was used to determine the severity of the disease. Result: The serum levels of IL-2 and TNF-α in patients with psoriasis were significantly greater than those of the controls (P < 0.01). It was found that the two cytokines were significantly elevated with increasing PASI score (P < 0.05). There was a positive correlation between cytokine levels and disease duration. There was a significant increase in the level of TNF-α in the group of smokers compared with non-smokers, with no significant increase in the level of IL-2. There was no significant sex-related difference. Conclusion: The serum IL-2 and TNF-α levels were identified to be elevated relative to the severity and duration of psoriasis and, therefore, have been established as effective inflammatory mediators in disease activity. The findings support the use of IL-2 and TNF-α as immunological biomarkers to track disease progression.
Downloads
References
1. Griffiths, C. E. M., & Barker, J. N. W. N. (2007). Pathogenesis and clinical features of psoriasis. The Lancet, 370(9583), 263–271.
https://doi.org/10.1016/S0140-6736(07)61128-3
2. Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007). Pathogenesis and therapy of psoriasis. Nature, 445(7130), 866–873.
https://doi.org/10.1038/nature05663
3. Boehncke, W. H., & Schön, M. P. (2015). Psoriasis. The Lancet, 386(9997), 983–994.
https://doi.org/10.1016/S0140-6736(14)61909-7
4. Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017). Psoriasis and comorbid diseases. Journal of the American Academy of Dermatology, 76(3), 377–390.
https://doi.org/10.1016/j.jaad.2016.07.064
5. Nestle, F. O., Kaplan, D. H., & Barker, J. (2009). Psoriasis. New England Journal of Medicine, 361(5), 496–509.
https://doi.org/10.1056/NEJMra0804595
6. Lowes, M. A., Suarez-Farinas, M., & Krueger, J. G. (2014). Immunology of psoriasis. Annual Review of Immunology, 32, 227–255.
https://doi.org/10.1146/annurev-immunol-032713-120225
7. Nickoloff, B. J., & Wrone-Smith, T. (1999). The role of T lymphocytes in psoriasis. Journal of Dermatological Science, 20(1), 1–10.
8. Cai, Y., Fleming, C., & Yan, J. (2012). New insights of T cells in the pathogenesis of psoriasis. Cellular & Molecular Immunology, 9(4), 302–309.
https://doi.org/10.1038/cmi.2012.15
9. Bradley, J. R. (2008). TNF-mediated inflammatory disease. Journal of Pathology, 214(2), 149–160.
https://doi.org/10.1002/path.2287
10. Victor, F. C., & Gottlieb, A. B. (2002). TNF-alpha and apoptosis: Implications for the pathogenesis and treatment of psoriasis. Journal of Drugs in Dermatology, 1(3), 264–275.
11. Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008). Tumor necrosis factor antagonist mechanisms of action. Pharmacology & Therapeutics, 117(2), 244–279.
https://doi.org/10.1016/j.pharmthera.2007.10.001
12. Feldmann, M., & Maini, R. N. (2001). Role of cytokines in rheumatoid arthritis and other chronic inflammatory diseases. Annual Review of Immunology, 19, 163–196.
https://doi.org/10.1146/annurev.immunol.19.1.163
13. Krueger, J. G. (2002). The immunologic basis for the treatment of psoriasis with new biologic agents. Journal of the American Academy of Dermatology, 46(1), 1–23.
https://doi.org/10.1067/mjd.2002.120544
14. Ghoreschi, K., Weigert, C., & Röcken, M. (2007). Immunopathogenesis of psoriasis. Clinical Dermatology, 25(6), 574–579.
https://doi.org/10.1016/j.clindermatol.2007.08.010
15. Boyman, O., & Sprent, J. (2012). The role of interleukin-2 during homeostasis and activation of the immune system. Nature Reviews Immunology, 12(3), 180–190.
https://doi.org/10.1038/nri3156
16. Malek, T. R. (2008). The biology of interleukin-2. Annual Review of Immunology, 26, 453–479.
https://doi.org/10.1146/annurev.immunol.26.021607.090357
17. Kryczek, I., Bruce, A. T., Gudjonsson, J. E., Johnston, A., Aphale, A., Vatan, L., Szeliga, W., Wang, Y., Liu, Y., & Zou, W. (2008). Induction of IL-17+ T cell trafficking and development by IFN-γ. Journal of Immunology, 181(7), 4733–4741.
https://doi.org/10.4049/jimmunol.181.7.4733
18. Di Cesare, A., Di Meglio, P., & Nestle, F. O. (2009). The IL-23/Th17 axis in the immunopathogenesis of psoriasis. Journal of Investigative Dermatology, 129(6), 1339–1350.
https://doi.org/10.1038/jid.2009.59
19. Naldi, L., & Mercuri, S. R. (2009). Smoking and psoriasis. British Journal of Dermatology, 160(3), 467–469.
https://doi.org/10.1111/j.1365-2133.2008.08951.x
20. El-Mongy, S., Fathy, H., Abdelaziz, A., Omran, E., George, S., & El-Mesidy, M. (2016). Influence of smoking on cytokine expression in psoriasis. British Journal of Dermatology, 174(5), 1068–1076.
https://doi.org/10.1111/bjd.14344
21. Reich, K., Nestle, F. O., Papp, K., Ortonne, J. P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. M. (2005). Infliximab induction and maintenance therapy for psoriasis. The Lancet, 366(9494), 1367–1374.
https://doi.org/10.1016/S0140-6736(05)67566-6
22. Gordon, K. B., Langley, R. G., Leonardi, C., Toth, D., Menter, A., Kang, S., Kerdel, F., Silverman, S. L., & Gu, Y. (2006). Clinical response to adalimumab in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology, 55(4), 598–606.
https://doi.org/10.1016/j.jaad.2006.05.027
23. Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., Gottlieb, A. B., & Etanercept Psoriasis Study Group. (2003). Etanercept as monotherapy in patients with psoriasis. New England Journal of Medicine, 349(21), 2014–2022.
https://doi.org/10.1056/NEJMoa030409
24. Roser, L. A., Boyman, O., & Sprent, J. (2024). Revival of recombinant interleukin-2 therapy: Redefining the role of IL-2 in autoimmune disease. Immunological Investigations, 53(8), 1234–1246.
25. Lorenzon, R., Ferreira, R. C., & Bluestone, J. A. (2024). The universal effects of low-dose interleukin-2 across autoimmune diseases: Implications for psoriasis. Autoimmunity Reviews, 23(5), 102991.
https://doi.org/10.1016/j.autrev.2024.102991
26. Coimbra, S., Oliveira, H., Reis, F., Belo, L., Rocha, S., Quintanilha, A., & Santos-Silva, A. (2010). Circulating cytokine levels in psoriasis patients. Mediators of Inflammation, 2010, 1–6.
https://doi.org/10.1155/2010/759832
27. Gupta, R., Debbaneh, M., Liao, W., & Wu, J. J. (2018). Serum levels of IL-2 and TNF-α correlate with psoriasis severity and therapeutic response. Clinical and Experimental Dermatology, 43(4), 445–451.
https://doi.org/10.1111/ced.13459
28. Coimbra, S., Oliveira, H., Reis, F., Belo, L., Rocha, S., Quintanilha, A., & Santos-Silva, A. (2011). Interleukin-22, IL-17, and TNF-α levels in patients with psoriasis before and after treatment. Journal of the European Academy of Dermatology and Venereology, 25(6), 678–685.
https://doi.org/10.1111/j.1468-3083.2010.03838.x
29. Raychaudhuri, S. P., Mitra, A., Raychaudhuri, S. K., & Kundu-Raychaudhuri, S. (2014). Regulatory role of cytokines in psoriasis. Clinical Reviews in Allergy & Immunology, 47(2), 135–145.
https://doi.org/10.1007/s12016-013-8409-9
30. Siemińska, I., Nowicka-Sauer, K., & Jassem, E. (2020). TNF-α and IL-2 signaling in chronic inflammatory diseases. Postępy Dermatologii i Alergologii, 37(5), 615–621.
https://doi.org/10.5114/ada.2020.101585
31. Matei-Man, A. M., Bălănescu, A., & Mărculescu, C. (2021). TNF-α gene expression and chronic inflammation in psoriasis. Experimental and Therapeutic Medicine, 22(2), 1–7.
https://doi.org/10.3892/etm.2021.10392
32. Gonçalves, M. B. S., Costa, M. C., Andrade, P., & Selores, M. (2019). Gender differences in immune response in psoriasis. Dermatology Research and Practice, 2019, 1–8.
https://doi.org/10.1155/2019/7583567
33. Naldi, L., Peli, L., & Parazzini, F. (2010). Association of smoking habits with severity of psoriasis. British Journal of Dermatology, 162(1), 106–110.
https://doi.org/10.1111/j.1365-2133.2009.09457.x
34. Blauvelt, A., Chiricozzi, A., & Krueger, J. G. (2020). The role of TNF-α and IL-17 pathways in psoriasis. Journal of the European Academy of Dermatology and Venereology, 34(1), 3–14.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ali Mohammed Abd Al-ameer
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
